Dysport and Rash erythematous aggravated - a phase IV clinical study of FDA data

Summary:

Rash erythematous aggravated is found among people who take Dysport, especially for people who are female, 50-59 old, have been taking the drug for < 1 month.

The phase IV clinical study analyzes which people take Dysport and have Rash erythematous aggravated. It is created by eHealthMe based on reports of 4,824 people who have side effects when taking Dysport from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On Mar, 28, 2023

4,824 people reported to have side effects when taking Dysport.
Among them, 13 people (0.27%) have Rash erythematous aggravated.

What is Dysport?

Dysport has active ingredients of abobotulinumtoxina. It is often used in wrinkles. eHealthMe is studying from 4,850 Dysport users for its effectiveness, alternative drugs and more.

What is Rash erythematous aggravated?

Rash erythematous aggravated (worse redness of the skin) is found to be associated with 1,462 drugs and 473 conditions by eHealthMe.

Number of Dysport and Rash erythematous aggravated reports submitted per year:

Could Dysport cause Rash erythematous aggravated?

Time on Dysport when people have Rash erythematous aggravated *:

Gender of people who have Rash erythematous aggravated when taking Dysport *:

female: 100 %
male: 0.0 %

Age of people who have Rash erythematous aggravated when taking Dysport *:

Common drugs people take besides Dysport *:

Multivitamin: 1 person, 7.69%
Avage: 1 person, 7.69%

Common side effects people have besides Rash erythematous aggravated *:

Headache (pain in head): 3 people, 23.08%
Fatigue (feeling of tiredness): 3 people, 23.08%
Breathing Difficulty: 3 people, 23.08%
Neuromuscular Toxicity (toxic effect to combination of the nervous system and the muscles): 2 people, 15.38%
Injection Site Mass: 2 people, 15.38%
Weakness: 2 people, 15.38%
Gait Disturbance: 2 people, 15.38%
Eyelid Ptosis (falling of the upper or lower eyelid): 2 people, 15.38%
Lacrimation Increased: 2 people, 15.38%
Drug Hypersensitivity: 2 people, 15.38%

Common conditions people have *:

Skin Wrinkling (wrinkle on skin): 7 people, 53.85%
Stroke (sudden death of a portion of the brain cells due to a lack of oxygen): 1 person, 7.69%
Muscle Spasticity (tight or stiff muscles and an inability to control those muscles): 1 person, 7.69%
Epilepsy (common and diverse set of chronic neurological disorders characterized by seizures): 1 person, 7.69%

* Approximation only. Some reports may have incomplete information.

Do you take Dysport and have Rash erythematous aggravated?

Check whether Rash erythematous aggravated is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related studies

How severe was Rash erythematous aggravated and when was it recovered:

Rash erythematous aggravated in Dysport

Expand to all the drugs that have ingredients of abobotulinumtoxina:

Rash erythematous aggravated and drugs with ingredients of abobotulinumtoxina

Alternative drugs to, pros and cons of Dysport:

Dysport (4,850 reports)

Common Dysport side effects:

Drug ineffective: 955 reports
Weakness: 486 reports
Headache (pain in head): 363 reports
Swallowing difficulty: 321 reports
Fatigue (feeling of tiredness): 248 reports
Breathing difficulty: 243 reports
Dizziness: 237 reports

Browse all side effects of Dysport:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Rash erythematous aggravated treatments and more:

Rash erythematous aggravated (32 reports)

COVID vaccines that are related to Rash erythematous aggravated:

Common drugs associated with Rash erythematous aggravated:

All the drugs that are associated with Rash erythematous aggravated:

Rash erythematous aggravated (1,462 drugs)

Common conditions associated with Rash erythematous aggravated:

All the conditions that are associated with Rash erythematous aggravated:

Rash erythematous aggravated (473 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on abobotulinumtoxina (the active ingredients of Dysport) and Dysport (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.